Parkinson’s disease is a debilitating disorder characterised by movement disorders, including tremor, cognitive dysfunction and non-motor impairments. It is the second most common age-related neurodegenerative disease with ~10 million sufferers worldwide, but the causes of tremor are poorly understood and treatment is wholly inadequate.
Parkinson's Disease and related disorders
α-Synuclein (α-Syn) pathology is inextricably linked to the pathogenesis of Parkinson’s disease (PD), yet we have very limited understanding why specific neuronal populations are vulnerable to α-Syn-related PD pathology while others are much more resistant.
1. What is the Person with Parkinson's community knowledge and experience of existing voice assisted technology?
2. What is the knowledge, experience and attitudes of Speech and Language Therapists towards voice assisted technology in practice?
Project Aim(s): PD-MitoQUANT is an Innovative Medicines Initiative (IMI)Innovative Medicines Initiative (IMI) (www.imi.europa.eu) project that brings together academic experts, small and medium enterprises (SMEs), pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA)European Federation of Pharmaceutical Industries and Associations (EFPIA) (www.efpia.eu) and patient advocacy organisation Parkinson’s UKParkinson’s UK (www.p
Project Aim(s): To investigate bone morphogenetic protein 2 as a therapeutic for Parkinson's disease (PD).
Project Aim(s): The development of neurotrophic factor therapy for Parkinson's disease (PD).
Project Aim(s): To support national and local Parkinson’s disease service planning by three linked work packages.
The first maps the prevalence of Parkinson’s disease and service availability for people with Parkinson’s, across each of the nine Community Healthcare Organisation regions in Ireland, to highlight mismatches between population needs and service provision.
One promising approach for the treatment of PD is cellular brain repair whereby the cells that have died in the condition are replaced by transplantation of healthy cells into the brain. However, this approach has faced several limitations including poor survival of the transplanted cells in the PD brain. To address this limitation, we have recently shown that biomaterials - that is, materials that have been specifically engineered to interact with living systems for therapeutic purposes – have the potential to dramatically improve cellular brain repair for PD.
Pagination
- Page 1
- Next page ››